A Phase 1/1b First-in-Human Study to Evaluate the Safety and Pharmacokinetics of BMS-986506 in Patients with Advanced Clear Cell Renal Cell Carcinoma

The primary objective of this phase 1/1b first-in-human study is to evaluate the safety and pharmacokinetics of BMS-986506 in patients diagnosed with advanced clear cell renal cell carcinoma. This assessment is critical for establishing the initial safety profile and determining the metabolic characteristics of the investigational product in a clinical setting.

The study population consists of 77 patients diagnosed with advanced clear cell renal cell carcinoma. The cohort includes both male and female participants. Based on the provided age range codes, the subjects fall within specific age categories. The sponsor did not provide additional information regarding lifestyle considerations or selection methodologies.

This Phase 1/1b, first-in-human study evaluates the safety and efficacy of BMS-986506 in patients with advanced clear cell renal cell carcinoma. The trial design involves a sequence of study visits, beginning with a screening visit to determine eligibility. Following enrollment, participants undergo periodic follow-up visits to monitor clinical responses and safety parameters. The process concludes with an end-of-study visit. The total duration of participant involvement is determined by individual clinical progress and specific study protocols. Early termination from the study may occur based on predefined discontinuation criteria or clinical necessity.

The assessment of efficacy in this phase 1 clinical trial for advanced clear cell renal cell carcinoma is not specified in the provided documentation.